Lo que el cardiólogo debe conocer sobre antidiabéticos orales e insulinas

1995, Overview of six years’ therapy of type 2 diabetes: a progressive disease (UKPDS 16), Diabetes, 44, 1249, 10.2337/diabetes.44.11.1249 Holman, 1998, Analysis of the United Kingdom Prospective Diabetes Study, Diabetes Res Clin Prac, 40, S21, 10.1016/S0168-8227(98)00038-2 Chiu, 2000, Beta cell function declines with age in glucose tolerant Caucasians, Clin Endocrinol, 53, 569, 10.1046/j.1365-2265.2000.01132.x Boden, 2002, Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and ß-cell dysfunction, Eur J Clin Invest, 32, 14, 10.1046/j.1365-2362.32.s3.3.x Kaiser, 2003, Glucotoxicity and beta-cell failure in type 2 diabetes mellitus, J Pediatr Endocrinol Metab, 16, 5, 10.1515/JPEM.2003.16.1.5 Stumvoll, 2005, Type 2 diabetes: principles of pathogenesis and therapy, Lancet, 365, 1333, 10.1016/S0140-6736(05)61032-X 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 1998, Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 1998, Effects of Intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 2005, Documento 2005 de consenso entre varias sociedades cientificas sobre pautas de manejo del paciente diabético tipo 2 en España, Av Diabetol, 21, 20 2007, Standards of medical care in diabetes, Diabetes Care, 30, S4, 10.2337/dc07-S004 Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation; 2005. Disponible en: http://www.idf.org. 2002, Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self—Management-2002, Update Endocrine Pract, 8, S40, 10.4158/EP.8.S1.40 2007, The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J, 28, 88 Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med, 348, 383, 10.1056/NEJMoa021778 Nathan, 2002, Initial management of glycemia in type 2 diabetes mellitus, N Engl J Med, 347, 1342, 10.1056/NEJMcp021106 Deeg, 2005, Basic approach to managing hyperglycemia for the non endocrinologist, Am J Cardiol, 96, 37E, 10.1016/j.amjcard.2005.06.003 Izucchi, 2002, Oral antihyperglycemic therapy for type 2 diabetes. scientific review, JAMA, 287, 360, 10.1001/jama.287.3.360 Nathan, 2006, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 29, 1963, 10.2337/dc06-9912 Nathan, 2006, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia, 49, 1711, 10.1007/s00125-006-0316-2 Nathan, 2006, Thiazolidinediones for initial treatment of type 2 diabetes?, N Engl J Med, 355, 2477, 10.1056/NEJMe068264 Yki-Jarvinen, 2004, Thiazolidinediones, N Engl J Med, 351, 1106, 10.1056/NEJMra041001 Kahn, 2006, Glycemic durability of rosiglitazone, metformine, or glyburide monotherapy, N Engl J Med, 355, 2427, 10.1056/NEJMoa066224 2006, Effect of rosiglitazone on the frecuency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial, Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8 Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 Home, 2007, Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis, N Engl J Med, 357, 1, 10.1056/NEJMoa073394 Yki-Jarvinen, 2001, Combination therapies with insulin in type 2 diabetes, Diabetes Care, 24, 758, 10.2337/diacare.24.4.758 Goudswaard, 2004, Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus, Cochrane Database Syst Rev, 10.1002/14651858.CD003418.pub2 Hirsch, 2005, Insulin analogues, N Engl J Med, 352, 174, 10.1056/NEJMra040832 Van der Berghe, 2001, Intensive insulin therapy in the critically ill patients, N Engl J Med, 345, 1359, 10.1056/NEJMoa011300 Van der Bergue, 2004, How does blood glucose control with insulin save lives in intensive care?, J Clin Invest, 114, 1187, 10.1172/JCI23506 Unpierrez, 2002, Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes, J Clin Endocrinol Metab, 87, 978, 10.1210/jc.87.3.978 Furnary, 1999, Continous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures, Ann Thorac Surg, 67, 352, 10.1016/S0003-4975(99)00014-4 Zerr, 1997, Glucose control lowers the risk of wound infection in diabetics after open heart operations, Ann Thorac Surg, 63, 356, 10.1016/S0003-4975(96)01044-2 Malmberg, 1999, Circulation, 99, 2626, 10.1161/01.CIR.99.20.2626 Malmberg, 2005, Intensive metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidility, Eur Heart J, 26, 650, 10.1093/eurheartj/ehi199 Garber, 2004, American College of Endocrinology position statement on inpatient diabetes and metabolic control, Endocr Pract, 10, 77, 10.4158/EP.10.1.77 Inzucchi, 2006, Management of hyperglycemia in the hospital setting, N Engl J Med, 355, 1903, 10.1056/NEJMcp060094